神经源性逼尿肌过度活动患者膀胱内A型肉毒毒素注射的长期停药情况:多中心研究
该多中心回顾性研究纳入140例接受膀胱内A型肉毒毒素注射治疗神经源性逼尿肌过度活动的神经系统患者,评估10年停药率。10年无停药生存率为49.1%,无失败生存率为73%,失败是最常见停药原因(43.7%),脊柱裂患者停药风险显著更高。
要点
- 10年无停药生存率49.1%,超半数患者10年内停药
- 失败为最常见停药原因,占43.7%
- 脊柱裂患者停药风险显著高于多发性硬化或脊髓损伤患者
核心结论
- 超过半数神经源性逼尿肌过度活动患者在首次注射后10年内停用膀胱内A型肉毒毒素。
- 脊柱裂患者是停药的高风险人群。
研究设计与样本
- 主要结局为10年停药率,其他结局包括治疗失败、停药原因及后续治疗,采用Kaplan-Meier法估计无停药生存率和无失败生存率。
主要发现
- 10年无停药生存率为49.1%,无失败生存率为73%。
- 停药最常见原因为治疗失败,占43.7%,其中原发性和继发性失败分别占17.2%和26.5%。
- 继发性失败发生于中位注射8次后,距首次注射中位时间80.1个月。
- 其他停药原因包括患者决定(28.1%)、非肉毒毒素A相关的尿失禁改善(14.1%)、神经系统病情进展(12.5%)和不良事件(1.6%)。
- 脊柱裂患者的无停药生存率显著低于多发性硬化或脊髓损伤患者(p=0.02)。
临床怎么用
- 临床应告知神经源性逼尿肌过度活动患者,膀胱内A型肉毒毒素注射长期治疗中约半数可能在10年内停药。
- 对脊柱裂患者应加强随访,关注早期停药风险。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 样本来自3家学术中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Data are lacking on long-term outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. The aim of this study was to assess the outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity after more than 10 years of followup. MATERIALS AND METHODS: We retrospectively reviewed the charts of all consecutive neurological patients who had received onabotulinumtoxin A or abobotulinumtoxin A intradetrusor injections for neurogenic detrusor overactivity between January 2002 and November 2007 at a total of 3 academic centers. The primary outcome measure was the 10-year discontinuation rate. Other outcomes of interest were failure, reasons for discontinuation and subsequent treatments of neurogenic detrusor overactivity. Discontinuation-free and failure-free survival was estimated by Kaplan-Meier analyses. RESULTS: A total of 140 patients were included in study. The 10-year discontinuation-free and failure-free survival rates were 49.1% and 73%, respectively. The most common reason for discontinuation was failure in 43.7% of cases, which was primary and secondary in 17.2% and 26.5%, respectively. Secondary failure occurred after a median of 8 injections and a median of 80.1 months from the first injection. Other reasons for discontinuation were patient decision in 28.1% of patients, nonbotulinum toxin A related improvement of urinary incontinence in 14.1%, neurological condition progression in 12.5% and an adverse event in 1.6%. Discontinuation-free survival was significantly poorer in patients with spina bifida than in patients with multiple sclerosis or spinal cord injury (p = 0.02). CONCLUSIONS: More than half of the patients with neurogenic detrusor overactivity discontinued intradetrusor botulinum toxin A within the first 10 years after the initial injection. Patients with spina bifida are at high risk for discontinuation.
引用
- Baron M, Peyronnet B, Aublé A, et al. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study. J Urol. 2019. PMID: 30359679. doi:10.1016/j.juro.2018.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。